Dyne Therapeutics (NASDAQ:DYN) Director Brian Posner Acquires 2,000 Shares of Stock

Dyne Therapeutics, Inc. (NASDAQ:DYN) Director Brian Posner purchased 2,000 shares of Dyne Therapeutics stock in a transaction that occurred on Monday, June 8th. The shares were bought at an average cost of $16.94 per share, with a total value of $33,880.00. Following the completion of the transaction, the director directly owned 24,500 shares of the company’s stock, valued at approximately $415,030. The trade was a 8.89% increase in their position. The purchase was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

Dyne Therapeutics Stock Performance

Shares of NASDAQ DYN opened at $17.92 on Wednesday. The stock has a 50 day moving average price of $18.26 and a 200 day moving average price of $18.22. Dyne Therapeutics, Inc. has a 52 week low of $8.06 and a 52 week high of $25.00. The company has a debt-to-equity ratio of 0.17, a quick ratio of 19.92 and a current ratio of 19.92. The stock has a market capitalization of $2.96 billion, a PE ratio of -5.57 and a beta of 1.09.

Dyne Therapeutics (NASDAQ:DYN) last issued its quarterly earnings results on Monday, May 11th. The company reported ($0.73) EPS for the quarter, beating the consensus estimate of ($0.77) by $0.04. During the same period last year, the firm earned ($1.05) EPS. Analysts predict that Dyne Therapeutics, Inc. will post -3 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several research firms have issued reports on DYN. Wall Street Zen upgraded Dyne Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Saturday, May 16th. Weiss Ratings restated a “sell (d-)” rating on shares of Dyne Therapeutics in a research note on Monday, April 20th. HC Wainwright dropped their price objective on Dyne Therapeutics from $60.00 to $50.00 and set a “buy” rating on the stock in a research note on Tuesday, March 3rd. Chardan Capital restated a “buy” rating and issued a $38.00 price objective on shares of Dyne Therapeutics in a research note on Monday, March 9th. Finally, Morgan Stanley dropped their price objective on Dyne Therapeutics from $50.00 to $47.00 and set an “overweight” rating on the stock in a research note on Monday, March 2nd. Three research analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $35.00.

Institutional Investors Weigh In On Dyne Therapeutics

Large investors have recently added to or reduced their stakes in the stock. JPMorgan Chase & Co. grew its position in Dyne Therapeutics by 9.0% during the third quarter. JPMorgan Chase & Co. now owns 3,365,245 shares of the company’s stock worth $42,570,000 after buying an additional 278,466 shares in the last quarter. Aberdeen Group plc grew its position in Dyne Therapeutics by 15.0% during the third quarter. Aberdeen Group plc now owns 556,733 shares of the company’s stock worth $7,043,000 after buying an additional 72,770 shares in the last quarter. Vanguard Group Inc. grew its position in Dyne Therapeutics by 27.6% during the third quarter. Vanguard Group Inc. now owns 9,760,414 shares of the company’s stock worth $123,469,000 after buying an additional 2,109,257 shares in the last quarter. SG Americas Securities LLC acquired a new stake in Dyne Therapeutics during the fourth quarter worth approximately $5,191,000. Finally, Rafferty Asset Management LLC grew its position in Dyne Therapeutics by 93.4% during the third quarter. Rafferty Asset Management LLC now owns 213,211 shares of the company’s stock worth $2,697,000 after buying an additional 102,963 shares in the last quarter. Institutional investors and hedge funds own 96.68% of the company’s stock.

About Dyne Therapeutics

Dyne Therapeutics is a clinical-stage biotechnology company specializing in the development of localized gene regulation therapies for serious rare diseases. The company’s proprietary FORCE (Facilitated Orthogonal Receptor?mediated Cargo Evaluation) platform is designed to enable targeted delivery of oligonucleotide and gene therapy modalities to skeletal and respiratory muscles. Dyne’s lead programs focus on Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1) and facioscapulohumeral muscular dystrophy (FSHD), with preclinical and early clinical studies evaluating safety, tolerability and tissue specificity.

Since its founding in 2019 by Flagship Pioneering, Dyne has advanced multiple product candidates using its modular delivery approach, which couples engineered ligands with therapeutic payloads to improve uptake into muscle cells.